Clinical Trial Update: NAPS-MS: NAtalizumab Effects on Parameters of Sleep in Patients With Multiple Sclerosis Experiencing Fatigue or Sleepiness [Phase 4]

View source ↗

Summary

Phase 4 trial assessing natalizumab’s effects on sleep parameters in relapsing-remitting multiple sclerosis patients experiencing fatigue or sleepiness.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Sclerosis Relapsing-remitting

Drugs mentioned

• Tysabri (Natalizumab)

Snippet

Sponsor: Cornerstone Health Care, PA | Conditions: Multiple Sclerosis, Relapsing-Remitting | Phase 4 | Status: COMPLETED